Paper31377149
Perspectives on urea cycle disorder management: Results of a clinician survey.
Enns GM and 4 others. Mol Genet Metab, 2019. Cited by 18 papers, by iCite.
Cite this record
ConductScience Library. Perspectives on urea cycle disorder management: Results of a clinician survey. Papers, record 31377149. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/31377149
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics9
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Disease Management | Major topic |
| Physicians | Major topic |
| Surveys and Questionnaires | Major topic |
| Urea Cycle Disorders, Inborn | Major topic |
| Humans | |
| Hyperammonemia | |
| Longitudinal Studies | |
| Quality of Life | |
| Urea |
Source PubMed
Cited by11
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 18 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42306244 | Long-Term Efficacy and Safety of Glycerol Phenylbutyrate in Japanese Patients With Urea Cycle Disorders: Results From a Phase 3 Switch-Over and 12-Month Extension Study. | JIMD Rep | 2026 | https://conductscience.org/library/papers/42306244 | PubMed |
| 41824151 | Emerging neurological and cognitive symptoms in patients with late-onset ornithine transcarbamylase deficiency: a narrative review. | Metab Brain Dis | 2026 | https://conductscience.org/library/papers/41824151 | PubMed |
| 41123737 | Development of patient-centric conceptual frameworks for symptoms and impacts of ornithine transcarbamylase deficiency (OTCD). | J Patient Rep Outcomes | 2025 | https://conductscience.org/library/papers/41123737 | PubMed |
| 40804416 | Clinical characteristics and long-term outcomes of 101 patients with urea cycle disorders in China. | Orphanet J Rare Dis | 2025 | https://conductscience.org/library/papers/40804416 | PubMed |
| 40102865 | Perspectives on long-term medical management of urea cycle disorders: insights from a survey of UK healthcare professionals. | Orphanet J Rare Dis | 2025 | https://conductscience.org/library/papers/40102865 | PubMed |
| 37480106 | Citrulline in the management of patients with urea cycle disorders. | Orphanet J Rare Dis | 2023 | https://conductscience.org/library/papers/37480106 | PubMed |
| 37245377 | Barriers to a successful healthcare transition for individuals with urea cycle disorders. | Mol Genet Metab | 2023 | https://conductscience.org/library/papers/37245377 | PubMed |
| 36620388 | Variable disease manifestations and metabolic management within a single family affected by ornithine transcarbamylase deficiency. | Mol Genet Metab Rep | 2022 | https://conductscience.org/library/papers/36620388 | PubMed |
| 36362876 | Three-Country Snapshot of Ornithine Transcarbamylase Deficiency. | Life (Basel) | 2022 | https://conductscience.org/library/papers/36362876 | PubMed |
| 35822089 | Natural history of arginase 1 deficiency and the unmet needs of patients: A systematic review of case reports. | JIMD Rep | 2022 | https://conductscience.org/library/papers/35822089 | PubMed |
| 34694515 | The burden of pharmacological treatment on health-related quality of life in people with a urea cycle disorder: a qualitative study. | J Patient Rep Outcomes | 2021 | https://conductscience.org/library/papers/34694515 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/31377149
GET https://conductscience.org/api/papers/v1/31377149/authors